Recently, molecular biomarkers including the 1p/19q co-deletion, BRAF mutation, IDH1/2 mutation, and TERT mutation have been widely used in the diagnosis, treatment, and prognostic prediction of gliomas. This evidence concerns the gene TERT and glioma.